For Over a Decade, No Systemic Therapy Has Shown Survival Superior to Sorafenib 1,4,5

TECENTRIQ + Avastin, the first and only cancer immunotherapy combination in 1L unresectable or mHCC, redefines treatment expectations with 1,4: